CS
BNTX icon

Candriam SCA’s BioNTech BNTX Stock Holding History

Candriam SCA’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.3M Buy
497,530
+9,163
+2% +$862K 0.21% 100
2026
Q1 		$43.4M Sell
488,367
-116,549
-19% -$12M 0.23% 99
2025
Q4 		$57.6M Buy
604,916
+15,464
+3% +$1.56M 0.29% 79
2025
Q3 		$58.1M Buy
589,452
+2,716
+0.5% +$290K 0.3% 78
2025
Q2 		$62.5M Sell
586,736
-84,219
-13% -$8.51M 0.36% 70
2025
Q1 		$61.1M Sell
670,955
-175,979
-21% -$19.7M 0.38% 60
2024
Q4 		$96.5M Sell
846,934
-80,230
-9% -$9.16M 0.56% 32
2024
Q3 		$110M Buy
927,164
+348,166
+60% +$32M 0.63% 29
2024
Q2 		$46.5M Buy
578,998
+418,695
+261% +$38.3M 0.28% 78
2024
Q1 		$14.8M Buy
160,303
+120,000
+298% +$11.5M 0.09% 208
2023
Q4 		$4.25M Sell
40,303
-20,000
-33% -$2.02M 0.03% 352
2023
Q3 		$6.55M Sell
60,303
-82,000
-58% -$9.07M 0.05% 281
2023
Q2 		$15.4M Sell
142,303
-10,080
-7% -$1.13M 0.11% 193
2023
Q1 		$17.5M Hold
152,383
– – 0.12% 186
2022
Q4 		$22.9M Sell
152,383
-63,033
-29% -$9.7M 0.15% 154
2022
Q3 		$29.1M Sell
215,416
-22,718
-10% -$3.47M 0.21% 108
2022
Q2 		$35.5M Sell
238,134
-4,000
-2% -$611K 0.29% 85
2022
Q1 		$41.3M Buy
242,134
+1,232
+0.5% +$207K 0.28% 87
2021
Q4 		$61.6M Buy
240,902
+127,705
+113% +$35M 0.39% 60
2021
Q3 		$30.9M Buy
113,197
+9,100
+9% +$2.89M 0.21% 118
2021
Q2 		$23.3M Buy
104,097
+16,336
+19% +$3.08M 0.16% 153
2021
Q1 		$6.87M Hold
87,761
– – 0.06% 318
2020
Q4 		$7.15M Sell
87,761
-259,776
-75% -$25.5M 0.06% 326
2020
Q3 		$24.1M Sell
347,537
-62,776
-15% -$4.5M 0.23% 112
2020
Q2 		$27.4M Buy
+410,313
New +$20.5M 0.29% 91

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
GP
GSK plc London $602M AUM

Candriam SCA's BNTX Position: Q2 2026 in Review

Candriam SCA increased its BioNTech (BNTX) stake by 1.9% in Q2 2026, buying an estimated $862K and bringing the position to 497,530 shares worth $46.3M. The position accounts for 0.21% of the portfolio, ranked #100.

Candriam SCA first reported a position in BNTX in Q2 2020 and has held it in 25 quarters since. The position peaked at $110M in Q3 2024. 281 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • Candriam SCA held 497,530 shares of BioNTech worth $46.3M as of Q2 2026.
  • Candriam SCA bought 9,163 BioNTech shares in Q2 2026, an estimated $862K.
  • BioNTech made up 0.21% of Candriam SCA's portfolio in Q2 2026, its #100 holding.
  • Candriam SCA first reported a position in BioNTech in Q2 2020 and has held it in 25 quarters since.
  • Candriam SCA's BioNTech position peaked at $110M in Q3 2024.
  • 281 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.